Arcadia Biosciences, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $4.9M | $5.0M | $4.5M | $7.4M | $6.8M |
| Cost of revenue | $3.1M | $3.0M | $2.2M | $6.1M | $8.7M |
| Selling, general & administrative | $7.0M | $9.6M | $8.2M | $15.0M | $22.9M |
| Research and development | $9,000 | $53,000 | $64,000 | $1.5M | $3.9M |
| Operating income | -$2.5M | -$3.6M | -$6.1M | -$14.0M | -$35.5M |
| Interest expense | — | — | — | — | $20,000 |
| Pretax income | -$2.3M | -$4.3M | -$5.3M | -$10.8M | -$16.1M |
| Income tax expense | $8,000 | $8,000 | $8,000 | $14,000 | $2,000 |
| Net income | -$2.3M | -$7.0M | -$14.0M | -$15.4M | -$14.7M |
| Balance Sheet | |||||
| Cash and equivalents | $259,000 | $4.2M | $6.5M | $20.6M | $28.7M |
| Current assets | $6.4M | $9.2M | $15.0M | $25.4M | $35.4M |
| Total assets | $6.5M | $13.5M | $19.7M | $28.9M | $43.9M |
| Current liabilities | $2.1M | $2.6M | $3.6M | $4.2M | $5.0M |
| Total liabilities | $2.4M | $7.3M | $7.0M | $8.0M | $12.7M |
| Stockholders' equity | $4.1M | $6.2M | $12.8M | $21.0M | $31.1M |
| Cash Flow Statement | |||||
| Cash from operations | -$4.7M | -$9.6M | -$15.3M | -$14.0M | -$25.9M |
| Depreciation and amortization | $32,000 | $58,000 | $111,000 | $439,000 | $929,000 |
| Stock-based compensation | $234,000 | $512,000 | $717,000 | $1.1M | $1.5M |
| Capital expenditure | $0 | $16,000 | $5,000 | $72,000 | $1.0M |
| Free cash flow | -$4.7M | -$9.6M | -$15.3M | -$14.0M | -$26.9M |
| Impairments | $0 | $36,000 | $0 | $160,000 | $1.4M |
Shares outstanding 2.1M · Free float 99.8%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.